Date published: 2025-10-14

1-800-457-3801

SCBT Portrait Logo
Seach Input

MJ33 (CAS 1135306-36-3)

5.0(1)
Write a reviewAsk a question

See product citations (3)

Alternate Names:
MJ33 Lithium salt; 1-Hexadecyl-3-(trifluoroethyl)-sn-glycero-2-phosphomethanol lithium
Application:
MJ33 is an active site-directed, specific, competitive, and reversible inhibitor of PLA2
CAS Number:
1135306-36-3
Purity:
≥90%
Molecular Weight:
498.48
Molecular Formula:
C22H43F3O6P•Li
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

MJ33 is a chemical compound utilized in biochemical research, particularly for its role as an inhibitor of phospholipase A2 (PLA2), an enzyme critical in the hydrolysis of phospholipids. This compound helps researchers understand the complex mechanisms of enzyme regulation and lipid metabolism. By studying MJ33′s inhibitory effects on PLA2, scientists can explore the enzyme′s involvement in cellular processes and its broader implications in lipid signaling pathways. The use of MJ33 in experimental applications contributes to the mapping of metabolic pathways that are essential for cell membrane integrity and function. Furthermore, the compound is instrumental in the study of signal transduction mechanisms, where alterations in lipid mediators play a significant role.


MJ33 (CAS 1135306-36-3) References

  1. Lysosomal-type PLA2 and turnover of alveolar DPPC.  |  Fisher, AB. and Dodia, C. 2001. Am J Physiol Lung Cell Mol Physiol. 280: L748-54. PMID: 11238016
  2. A competitive inhibitor of phospholipase A2 decreases surfactant phosphatidylcholine degradation by the rat lung.  |  Fisher, AB., et al. 1992. Biochem J. 288 (Pt 2): 407-11. PMID: 1463444
  3. Antioxidant protection by PECAM-targeted delivery of a novel NADPH-oxidase inhibitor to the endothelium in vitro and in vivo.  |  Hood, ED., et al. 2012. J Control Release. 163: 161-9. PMID: 22974832
  4. A novel nontoxic inhibitor of the activation of NADPH oxidase reduces reactive oxygen species production in mouse lung.  |  Lee, I., et al. 2013. J Pharmacol Exp Ther. 345: 284-96. PMID: 23475902
  5. Protection against LPS-induced acute lung injury by a mechanism-based inhibitor of NADPH oxidase (type 2).  |  Lee, I., et al. 2014. Am J Physiol Lung Cell Mol Physiol. 306: L635-44. PMID: 24487388
  6. Inhibition of the phospholipase A2 activity of peroxiredoxin 6 prevents lung damage with exposure to hyperoxia.  |  Benipal, B., et al. 2015. Redox Biol. 4: 321-7. PMID: 25637741
  7. Peroxiredoxins prevent oxidative stress during human sperm capacitation.  |  Lee, D., et al. 2017. Mol Hum Reprod. 23: 106-115. PMID: 28025393
  8. Peroxiredoxin 6 mediates acetaminophen-induced hepatocyte death through JNK activation.  |  Lee, DH., et al. 2020. Redox Biol. 32: 101496. PMID: 32171727
  9. Acidic Calcium-Independent Phospholipase A2 Regulates Eosinophil-Mediated Pathology during Filarial Manifestation of Tropical Pulmonary Eosinophilia.  |  Sharma, P., et al. 2021. J Immunol. 206: 722-736. PMID: 33441441
  10. Porcine Picornavirus 3C Protease Degrades PRDX6 to Impair PRDX6-mediated Antiviral Function.  |  Wang, C., et al. 2021. Virol Sin. 36: 948-957. PMID: 33721217
  11. A phospholipase A2 inhibitor decreases generation of thiobarbituric acid reactive substance during lung ischemia-reperfusion.  |  al-Mehdi, AB., et al. 1993. Biochim Biophys Acta. 1167: 56-62. PMID: 8461333
  12. Role of acidic Ca2+-independent phospholipase A2 in synthesis of lung dipalmitoyl phosphatidylcholine.  |  Fisher, AB. and Dodia, C. 1997. Am J Physiol. 272: L238-43. PMID: 9124374
  13. Crystal structure of the complex of bovine pancreatic phospholipase A2 with the inhibitor 1-hexadecyl-3-(trifluoroethyl)-sn-glycero-2-phosphomethanol,  |  Sekar, K., et al. 1997. Biochemistry. 36: 14186-91. PMID: 9369492

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

MJ33, 5 mg

sc-221947
5 mg
$256.00